Related Experiment Video
Updated: Jun 28, 2026

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
Published on: August 8, 2025
Arteriovenous Access Outcomes and Risk of Major Cardiovascular Events in Patients with Reduced Ejection Fraction: A
Nehal Naseer1, Nadeem Ahmed Siddiqui1, Fareed Ahmed Shaikh1
1Section of Vascular Surgery, Aga Khan University Hospital, Karachi, Pakistan.
Insights
Ejection fraction did not significantly affect arteriovenous fistula patency in end-stage renal disease patients. However, normal ejection fraction was linked to higher major adverse cardiovascular events, suggesting complex interactions needing more study.
Area of Science:
- Nephrology
- Cardiology
- Vascular Surgery
Background:
- End-stage renal disease (ESRD) necessitates vascular access for hemodialysis.
- Arteriovenous fistula (AVF) is the preferred access, but maturation and patency can be affected by patient comorbidities.
- Ejection fraction (EF), a measure of heart function, is a key comorbidity in ESRD patients.
Purpose of the Study:
- To investigate the relationship between preoperative ejection fraction and AVF maturation and patency in ESRD patients.
- To determine the incidence of major adverse cardiovascular events (MACE) following AVF creation in relation to EF.
Main Methods:
- Retrospective cohort study of 127 ESRD patients undergoing AVF creation (January 2015 - December 2020).
- Patients categorized into normal EF (Group A) and abnormal EF (Group B) based on American College of Cardiology guidelines.
- Analysis of demographics, procedural data, AVF patency, and MACE within one year post-surgery.
Main Results:
- AVF patency rates were comparable between normal EF (81.5%) and abnormal EF (88.6%) groups.
- Major adverse cardiovascular events were significantly higher in the normal EF group (39.1%) compared to the abnormal EF group (12.6%).
- Stroke occurred only in the normal EF group (6.5%); non-ST elevation myocardial infarction was the most frequent cardiac event in both groups.
Conclusions:
- Preoperative ejection fraction did not significantly impact AVF patency in ESRD patients.
- A trend towards lower patency was observed with increasing EF dysfunction.
- The elevated MACE risk in normal EF patients highlights a complex interplay of factors requiring further investigation.
Objective:
To evaluate the impact of ejection fraction on arteriovenous fistula maturation and patency, and to determine the incidence of major adverse cardiovascular events in end-stage renal disease patients undergoing arteriovenous fistula formation.
Methods:
The retrospective cohort study was conducted at Aga Khan University Hospital, Karachi, and comprised data of patients who underwent arteriovenous fistula creation between January 2015 and December 2020. Using the American College of Cardiology guidelines, the patients were categorised into normal ejection fraction group A and abnormal ejection fraction group B, with the latter further divided into mild, moderate and severe dysfunction subgroups. Data on demographics, procedural details, arteriovenous fistula patency, and major adverse cardiovascular events within one year postoperatively were analysed. Data was analysed using Stata version 15.
Results:
Of the 127 patients, 92(72.4%) were in group A; 47(51.08%) females and 45(48.91%) males with mean age 58.8 ± 13.3 years. The remaining 35(27.6%) patients were in group B; 24(68.6%) males and 11(31.43%) females with mean age 57.9±14.7 years. Arteriovenous fistula patency rates were comparable between the groups; 75(81.5%) in group A and 31(88.6%) in group B. Major adverse cardiovascular events rates were significantly higher in group A 36(39.1%) compared to group B 16(12.6%) (p>0.05). Stroke occurred exclusively in group A 6(6.5%), while non-ST elevation myocardial infarction was the most common cardiac event; 15(16.3%) in group A and 7(20%) in group B.
Conclusions:
Preoperative ejection fraction did not significantly impact arteriovenous fistula patency in end-stage renal disease patients, but increasing ejection fraction dysfunction could trend towards lower patency. The higher major adverse cardiovascular events risk in normal ejection fraction patients suggested a complex interplay of factors requiring further investigation.
Related Concept Videos
Hemodialysis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Return
What is Venous Return?
Venous return refers to the rate at which blood flows back to the heart from the body's peripheral veins. It's an integral part of the circulatory system as it...
